Tailoring antiseizure treatment with a wearable device: A proof‐of‐concept study in absence epilepsy
Epilepsia · 2025-07 · 66 (7) · 2295-2306
DOI: 10.1111/epi.18384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, online erschienen am 21.03.2025. Verfasst von Jaiver Macea und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Epilepsy Research, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Epilepsy, Absence, Wearable Electronic Devices, Anticonvulsants, Electroencephalography. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agentschap Innoveren en Ondernemen, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Objective
Typical absence seizures are underreported. We aimed to improve patient care using a wearable electroencephalograph (wEEG) at home and assess a machine learning (ML) pipeline for absence detection.
Methods
Patients with typical absences used a wEEG device 12–24 h 1 week after antiseizure medication (ASM) adjustments. Three‐hertz generalized spike–wave discharges (SWDs) ≥ 3 s were used as absence surrogates. After manual inspection, we used the results to guide medical treatment. The outcomes were seizure freedom, number of consecutive measurements without relapse, and side effects. Afterward, we used the ML pipeline on the recordings, and a neurologist reviewed the output. Review time and diagnostic performance were compared with manual inspection.
Results
Nineteen patients (12 female, median age = 24 years) were followed for a median of 5 months (range = 1–12). The median recording time for each session was 21.3 h (range = 10–24). Fifteen patients (79%) were seizure‐free during the last measurement, including seven of 11 (63%) diagnosed with refractory epilepsy. Ten patients relapsed after a median of 1–2 recordings (range = 1–6) without 3‐Hz SWDs. Side effects occurred in 21% of patients. Manual file inspection identified 806 3‐Hz SWDs of ≥3 s. The ML pipeline reduced a neurologist's median review time for 24‐h wEEG from 27 (range = 10–45) to 4.3 min (range = .1–10), with a sensitivity, precision, F1‐score, and false positives per hour of .8, .95, .87, and .007, respectively. Significance Home‐based wEEG allows patient monitoring after ASM adjustments, improving absence seizure management. The ML‐based pipeline performed well and was crucial in reducing review time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Epilepsy Research, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
- Department of Electrical Engineering, STADIUS Center for Dynamical Systems, Signal Processing, and Data Analytics, KU Leuven, Leuven, Belgium.
- Woman and Child, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
- Department of Neurology, Leuven University Hospitals, Leuven, Belgium.
ORCID-Profile: Jaiver Macea, Christos Chatzichristos, Miguel Bhagubai, Maarten De Vos, Wim Van Paesschen
Förderung
- Agentschap Innoveren en Ondernemen
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Macea, J., Chatzichristos, C., Bhagubai, M., De Vos, M., & Van Paesschen, W. (2025). Tailoring antiseizure treatment with a wearable device: A proof‐of‐concept study in absence epilepsy. Epilepsia, 66(7), 2295-2306. https://doi.org/10.1111/epi.18384
Vancouver
Macea J, Chatzichristos C, Bhagubai M, De Vos M, Van Paesschen W. Tailoring antiseizure treatment with a wearable device: A proof‐of‐concept study in absence epilepsy. Epilepsia. 2025;66(7):2295-2306. doi:10.1111/epi.18384
BibTeX
@article{Macea2025,
author = {Macea, Jaiver and Chatzichristos, Christos and Bhagubai, Miguel and De Vos, Maarten and Van Paesschen, Wim},
title = {Tailoring antiseizure treatment with a wearable device: A proof‐of‐concept study in absence epilepsy},
journal = {Epilepsia},
year = {2025},
volume = {66},
number = {7},
pages = {2295--2306},
doi = {10.1111/epi.18384}
}
EUVIMED